BioLineRx Ltd.

2019/2/8 10:53


AsiaNet 77375 (0199)

【テルアビブ(イスラエル)2019年2月8日PR Newswire=共同通信JBN】腫瘍学と免疫学に重点を置いた臨床段階のバイオ医薬品会社であるBioLineRx Ltd.(NASDAQ/TASE: BLRX)は8日、ADSおよび付随するワラント当たり0.55ドルの公募価格で、それぞれが普通株1株を表す2800万株の米国預託証券(ADS)および2800万株のADSを購入するワラントの以前公表した引受公募を完了したと発表した。ワラントは即時行使可能で、発効日から5年で失効し、行使価格はADS当たり0.75ドルである。公募による総調達資金額は、引受け割引および手数料ならびにBioLineRxが支払う公募費用の控除前で、ワラント行使を除いた場合、1540万ドルだった。この公募に含まれるすべての有価証券はBioLineRxにより売却された。BioLineRxは、公募からの純調達資金を、運転資金や臨床試験資金を含む可能性があるが、これに限らない一般的な企業目的に使用することを見込んでいる。

Oppenheimer & Co. Inc. が今回の公募の唯一の売り出し幹事を務めた。Maxim Group LLCが公募の共同幹事を務めた。

上述の証券は、証券取引委員会(SEC)に提出し、有効と宣言された発行登録書(File No. 333-222332)に従って発行された。当該募集に関連する最終目論見書の補足はSECに提出され、SECのウェブサイト で入手可能である。最終目論見書の補足のコピーは、以下から取得することもできる:

Oppenheimer & Co. Inc.

Syndicate Prospectus Department

85 Broad Street, 26th Floor

New York, New York 10004

電話 212-667-8055









ソース:BioLineRx Ltd.


Tim McCarthy

LifeSci Advisors, LLC


Tsipi Haitovsky

Public Relations


BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants


TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire=KYODO JBN/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company

focused on oncology and immunology, today announced that it has closed its

previously announced underwritten public offering of 28,000,000 American

Depositary Shares ("ADSs"), each representing one of its ordinary shares, and

warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per

ADS and accompanying warrant. The warrants are exercisable immediately, expire

five years from the date of issuance and have an exercise price of $0.75 per

ADS. The gross proceeds of the offering were $15.4 million, before deducting

underwriting discounts and commissions and offering expenses payable by

BioLineRx, and excluding the exercise of any warrants. All of the securities in

the offering were sold by BioLineRx.  BioLineRx anticipates using the net

proceeds from the offering for general corporate purposes, which may include,

but are not limited to, working capital and funding clinical trials.  

Oppenheimer & Co. Inc. acted as sole book-running manager for the offering.

Maxim Group LLC acted as co-manager for the offering.

The securities described above were issued pursuant to a shelf registration

statement (File No. 333-222332) that was previously filed with, and declared

effective by, the Securities and Exchange Commission ("SEC"). A final

prospectus supplement related to the offering has been filed with the SEC and

is available on the SEC's website located at Copies of the final

prospectus supplement may also be obtained from Oppenheimer & Co. Inc.,

85 Broad St., 26th Floor, New York, New York 10004, Attention: Syndicate

Prospectus Department, or by telephone: (212) 667-8055 or by email:

This press release does not constitute an offer to sell or a solicitation of an

offer to buy nor shall there be any sale of these securities in any state or

jurisdiction in which such offer, solicitation or sale would be unlawful prior

to registration or qualification under the securities laws of any such state or


About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology.

The Company in-licenses novel compounds, develops them through pre-clinical

and/or clinical stages, and then partners with pharmaceutical companies for

advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy

platform, which has successfully completed a Phase 2a study for

relapsed/refractory acute myeloid leukemia ("AML") and is in the midst of a

Phase 2b study as an AML consolidation treatment and has initiated a Phase 3

study in stem cell mobilization for autologous transplantation; and AGI-134, an

immunotherapy treatment in development for multiple solid tumors, which has

recently initiated a Phase 1/2a study. In addition, BioLineRx has a strategic

collaboration with Novartis for the co-development of selected Israeli-sourced

novel drug candidates; a collaboration agreement with MSD (known as Merck in

the United States and Canada), on the basis of which the Company is conducting

a Phase 2a study in pancreatic cancer using the combination of BL-8040 and

KEYTRUDA(R) (pembrolizumab), and a collaboration agreement with Genentech Inc.,

a member of the Roche Group, to investigate the combination of BL-8040 and

Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor

indications and AML.

Various statements in this release concerning BioLineRx's future expectations

constitute "forward-looking statements" within the meaning of the Private

Securities Litigation Reform Act of 1995. These statements include words such

as "may," "expects," "anticipates," "believes," and "intends," and describe

opinions about future events. These forward-looking statements involve known

and unknown risks and uncertainties that may cause the actual results,

performance or achievements of BioLineRx to be materially different from any

future results, performance or achievements expressed or implied by such

forward-looking statements. Some of these risks are: changes in relationships

with collaborators; the impact of competitive products and technological

changes; risks relating to the development of new products; and the ability to

implement technological improvements. These and other factors are more fully

discussed in the "Risk Factors" section of BioLineRx's most recent annual

report on Form 20-F filed with the Securities and Exchange Commission on March

6, 2018 and BioLineRx's other filings with the Securities and Exchange

Commission. In addition, any forward-looking statements represent BioLineRx's

views only as of the date of this release and should not be relied upon as

representing its views as of any subsequent date. BioLineRx does not assume any

obligation to update any forward-looking statements unless required by law.

SOURCE BioLineRx Ltd.

CONTACT: Tim McCarthy, LifeSci Advisors, LLC, +1-212-915-2564,; Tsipi Haitovsky, Public Relations, +972-52-598-9892,